Back

Impact of severe mitral regurgitation on patients with 'De Novo' heart failure and reduced ejection fraction: baseline characteristics and survival analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Epidemiology, prognosis, and outcome in chronic heart failure (3) Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Miguel Mejuto Blanco

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

3 More presentations in this session

Presentation thumbnail
Quantifying the impact of real-world evidence: the sacubitril/valsartan experience
Doctor S. Rathore (Kankakee, US)
Abstract Slides Video
Presentation thumbnail
In patients with heart failure with unplanned admission to hospital lack of improvement in quality-of-life 2 months after discharge identifies individuals at very high risk of readmission or death.
Mrs M. Mcginlay (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Heart rate control in heart failure: insights from nationwide multicenter registry HEROES.
Professor J. Kasprzak (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Epidemiology, prognosis, and outcome in chronic heart failure (3)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Impact of severe mitral regurgitation on patients with 'De Novo' heart failure and reduced ejection fraction: baseline characteristics and survival analysis
thumbnail
Congress Presentation
Prognostic significance of mitral regurgitation in acute heart failure stratified by ejection fraction
thumbnail
Congress Presentation
The power of optimal medical therapy in heart failure with secondary mitral regurgitation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources